Retatrutide, Tirzepatide and Semaglutide: Comparing the Research

Retatrutide, tirzepatide and semaglutide share a research context, but their names do not describe identical molecules, trial populations or regulatory positions. A useful comparison starts with the question each study asked. Percentage weight change, blood-glucose control and cardiovascular events are different outcomes, even when the same molecule appears in all three discussions.

At a glance:

• Receptor targets describe a mechanism, not a clinical ranking.

• Direct comparisons need their population, comparator and follow-up attached.

• A sponsor announcement and a published trial report deserve different labels.

• Findings for a controlled study formulation do not validate a research vial.

Publisher disclosure: Bio Research LLC operates Bio Peptides Labs. This commercially interested, AI-assisted summary is not an independent scientific review. The selected-source access scope is dated November 8, 2026 below.

1. What distinguishes the three molecules?

Semaglutide acts at the GLP-1 receptor; tirzepatide acts at GIP and GLP-1 receptors. Retatrutide adds glucagon-receptor activity. These targets are identified in the SELECT abstract, Zepbound label and TRIUMPH-2 abstract. Counting receptors alone cannot establish the size, durability or safety of a clinical effect.

Wegovy contains semaglutide and Zepbound contains tirzepatide; FDA identifies both as approved weight-reduction medicines in specified populations. Approval belongs to the regulated product and its indication. FDA product context

The FDA notice accessed for this article states that retatrutide is not an ingredient in an FDA-approved drug and has not been established as safe and effective for any condition. A positive trial or news release does not change that status by itself. The notice also distinguishes unapproved versions of semaglutide and tirzepatide from approved products. FDA notice

2. Which comparisons actually randomized people between drugs?

SURMOUNT-5, published in 2025, directly compared tirzepatide with semaglutide in 751 adults with obesity without type 2 diabetes. This randomized, open-label trial assessed percentage weight change at 72 weeks. Reported average changes were −20.2% and −13.7%, respectively. Gastrointestinal events were the most common adverse events in both groups. Lilly funded the trial. Original SURMOUNT-5 abstract

This supports a comparison under those trial conditions. Open-label means the assigned treatment was known; it does not erase randomization, but it belongs in the interpretation. The result is not a comparison of every semaglutide formulation or regimen, and it does not rank all possible health outcomes.

There is also a newer direct-comparison announcement. On October 28, 2026, Lilly reported topline TRANSCEND-T2D-2 results comparing retatrutide with Ozempic in adults with type 2 diabetes over 80 weeks. The sponsor reported greater A1C reduction and weight reduction with retatrutide. This article treats that source as a sponsor announcement, not an independently appraised full trial paper. Dated sponsor release

The distinction matters: a diabetes trial against the specified Ozempic regimen does not answer every obesity-treatment comparison against semaglutide. It would also be inaccurate to say that no direct retatrutide–semaglutide comparison has been reported.

3. How far has retatrutide research progressed?

Retatrutide evidence now extends beyond its frequently cited 2023 phase 2 obesity study. The published TRIUMPH-2 phase 3 trial randomized 1,152 adults with type 2 diabetes and a body-mass index of at least 27. Its main weight endpoint was assessed at 80 weeks against placebo. The abstract reports weight improvements, alongside more gastrointestinal events, hypotension and altered-sensation events in retatrutide groups. It also reports treatment discontinuations and Lilly funding. TRIUMPH-2 original abstract, published online September 29, 2026

That is placebo-controlled evidence, not a retatrutide-versus-tirzepatide result. The separate TRIUMPH-5 registry record describes that direct comparison. When checked November 8, its record was active, not recruiting, with no results posted and estimated primary completion in November 2026. An estimated completion month is not a result or a guarantee of when results will appear. TRIUMPH-5 registry

Our selection is not a complete catalogue of retatrutide studies. It establishes why an article relying only on phase 2 evidence would be incomplete, while leaving unpublished comparisons unresolved.

4. Why do headline percentages resist a simple ranking?

Use this map before moving a number from one study into another comparison:

SELECT illustrates the endpoint difference. Among 17,604 participants, the cardiovascular composite occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over average follow-up of about 40 months. Adverse events leading to permanent treatment discontinuation were more frequent with semaglutide. Novo Nordisk funded the study. Original SELECT abstract

A cardiovascular-event result cannot be replaced with a weight-loss percentage. Likewise, percentages from separate trials differ in eligibility, follow-up, comparator, treatment discontinuation and missing-data handling. An estimand specifies the effect the analysis aims to estimate, including how events such as stopping treatment are handled. Record it before comparing headline numbers.

5. How can the research be used responsibly?

Build a short evidence record containing the exact molecule, population, comparator, primary endpoint, follow-up, adverse events, funding and publication type. Mark information unavailable when an abstract or announcement does not supply it. Keep exploratory outcomes separate from the study's primary question.

Our guide to reading a peptide study develops that workflow. For a different endpoint problem, the retatrutide and GHK-Cu article separates weight research from skin, hair and combination claims. Laboratory budgeting belongs in a separate research-pricing comparison; price does not resolve evidence gaps.

Review method and source access

Sources accessed November 8, 2026: selected original-study abstracts, FDA notices, the TRIUMPH-5 registry and Lilly's dated topline release. Complete trial papers, supplements and participant-level data were not comprehensively reviewed. This is a selected-source comparison, not a systematic review or independent safety assessment.

Catalog materials are for lawful laboratory research, not human or veterinary use. This article supplies no dosing or administration instructions and does not equate catalog materials with approved medicines or trial formulations.